Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
- Submitting institution
-
The University of Leeds
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- UOA2-709
- Type
- D - Journal article
- DOI
-
10.1093/annonc/mdw665
- Title of journal
- Annals of Oncology
- Article number
- -
- First page
- 754
- Volume
- 28
- Issue
- 4
- ISSN
- 0923-7534
- Open access status
- Compliant
- Month of publication
- December
- Year of publication
- 2016
- URL
-
https://doi.org/10.1093/annonc/mdw665
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
20
- Research group(s)
-
-
- Citation count
- 42
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- Contribution A: Contribution to the conception and design of the study,Contribution to the organisation of the conduct of the study,Contribution to carrying out the study,Contribution to analysis and interpretation of the study data
Contribution B: The author helped draft the output,Critique the output for important intellectual content
- Non-English
- No
- English abstract
- -
